Results 101 to 110 of about 786,314 (373)

Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System

Obstetrics and Gynecology, 2022
The safety profile of booster doses of coronavirus disease 2019 (COVID-19) vaccine is reassuring and comparable with that of primary COVID-19 vaccine in pregnant people.
P. Moro, C. Olson, Bicheng Zhang, P. Marquez, Penelope Strid   +4 more
semanticscholar   +1 more source

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

Molecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim   +11 more
wiley   +1 more source

DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines

Pharmacoepidemiology
Background/Objectives: Controversy exists over the use of passive reporting systems, especially the Vaccine Adverse Event Reporting System, in risk assessment.
Matthew Halma, Joseph Varon
doaj   +1 more source

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

Inhaled corticosteroids versus long-acting beta -agonists for chronic obstructive pulmonary disease (Review). [PDF]

, 2011
Long-acting beta(2)-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic obstructive pulmonary disease. These interventions are often taken together in a combination inhaler.
Agarwal, Anderson, Appleton, Barnes, Borgstrom, Borgstrom, Boyd, Burge, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverly, Campbell, Campell, Cazzola, Cazzola, Celli, Celli, Celli, Celli, Corhay, Dahl, Della Cioppa, Egede, Ferguson, Ferguson, Gosman, Greefhorst, Halpin, Halpin, Halpin, Hanania, Hanania, Hanania, Higgins, Horstman, Hunjan, Hunjan, Hunjan, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Keene, Korsgaard, Kristufek, Lange, Lofdahl, Lofdahl, Lofdahl, Lofdahl, Lyseng-Williamson, Mahler, Mahler, Mahler, McGarvey, Milanowski, Nannini, Nannini, Nannini Luis, Nitschmann, Pauwels, Pauwels, Reynolds, Rodrigo, Rodrigo, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Szafranski, Vestbo, Vestbo, Vestbo, Vestbo, Vestbo, Yang   +105 more
core   +2 more sources

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib

Frontiers in Pharmacology
BackgroundSunitinib is approved for the treatment of metastatic renal cell carcinoma (mRCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and advanced pancreatic neuroendocrine tumors (PNET).
Xusheng Zhang, Xiuli Ren, Tianyu Zhu, Wanjin Zheng, Wanjin Zheng, Chengwu Shen, Cuicui Lu   +6 more
doaj   +1 more source

ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
In SMAD4‐positive pancreatic ductal adenocarcinoma (PDAC), integrin subunit alpha V (ITGAV) activates latent TGF‐β, which binds to the TGF‐β receptor and phosphorylates SMAD2/3. The activated SMAD2/3 forms a complex with SMAD4, and together they translocate to the nucleus, modulating gene expression to promote proliferation, migration, and invasion. In
Daniel K. C. Lee, Keyue Chen, Ryan Loke, Xiang Li, David Liubart, Golam T. Saffi, Jonathan T. S. Chow, Ché M. P. Melo, Lydia To, Leonardo Salmena   +9 more
wiley   +1 more source

Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an α-blocker (tamsulosin) : study protocol for a randomized controlled trial [PDF]

, 2014
Peer reviewedPublisher ...
Anson, Ken, Burr, Jennifer, Kilonzo, Mary, Lam, Thomas, MacLennan, Graeme Stewart, McClinton, Sam, McDonald, Alison, McPherson, Gladys, N'Dow, James, Pickard, Robert, Starr, Kathryn, SUSPEND Study Group, Thomas, Ruth   +12 more
core   +2 more sources

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS

Frontiers in Immunology
BackgroundThe advent of tisagenlecleucel has been a major advance in the pharmacological treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and adolescents.
Ganggang Wang, Lin Su, Yanjun Liu, Xiaohan Yang, Yi Li, Qi Mei, Qi Mei, Wen Gao   +7 more
doaj   +1 more source

Adverse events after Fluzone® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011–2013 [PDF]

Vaccine, 2013
In May 2011, the first trivalent inactivated influenza vaccine exclusively for intradermal administration (TIV-ID) was licensed in the US for adults aged 18-64 years.To characterize adverse events (AEs) after TIV-ID reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system.We searched VAERS for US ...
Tom T. Shimabukuro, Pedro L. Moro, Karen R. Broder, Theresa Harrington, Maria Cano, David Menschik, Oidda I. Museru   +6 more
openaire   +3 more sources